Cargando…
Percutaneous ablation of pancreatic cancer
Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in c...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Baishideng Publishing Group Inc
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124972/ https://www.ncbi.nlm.nih.gov/pubmed/27956791 http://dx.doi.org/10.3748/wjg.v22.i44.9661 |
_version_ | 1782469909669740544 |
---|---|
author | D’Onofrio, Mirko Ciaravino, Valentina De Robertis, Riccardo Barbi, Emilio Salvia, Roberto Girelli, Roberto Paiella, Salvatore Gasparini, Camilla Cardobi, Nicolò Bassi, Claudio |
author_facet | D’Onofrio, Mirko Ciaravino, Valentina De Robertis, Riccardo Barbi, Emilio Salvia, Roberto Girelli, Roberto Paiella, Salvatore Gasparini, Camilla Cardobi, Nicolò Bassi, Claudio |
author_sort | D’Onofrio, Mirko |
collection | PubMed |
description | Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of non-resectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques (radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review. |
format | Online Article Text |
id | pubmed-5124972 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Baishideng Publishing Group Inc |
record_format | MEDLINE/PubMed |
spelling | pubmed-51249722016-12-12 Percutaneous ablation of pancreatic cancer D’Onofrio, Mirko Ciaravino, Valentina De Robertis, Riccardo Barbi, Emilio Salvia, Roberto Girelli, Roberto Paiella, Salvatore Gasparini, Camilla Cardobi, Nicolò Bassi, Claudio World J Gastroenterol Editorial Pancreatic ductal adenocarcinoma is a highly aggressive tumor with an overall 5-year survival rate of less than 5%. Prognosis and treatment depend on whether the tumor is resectable or not, which mostly depends on how quickly the diagnosis is made. Chemotherapy and radiotherapy can be both used in cases of non-resectable pancreatic cancer. In cases of pancreatic neoplasm that is locally advanced, non-resectable, but non-metastatic, it is possible to apply percutaneous treatments that are able to induce tumor cytoreduction. The aim of this article will be to describe the multiple currently available treatment techniques (radiofrequency ablation, microwave ablation, cryoablation, and irreversible electroporation), their results, and their possible complications, with the aid of a literature review. Baishideng Publishing Group Inc 2016-11-28 2016-11-28 /pmc/articles/PMC5124972/ /pubmed/27956791 http://dx.doi.org/10.3748/wjg.v22.i44.9661 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. |
spellingShingle | Editorial D’Onofrio, Mirko Ciaravino, Valentina De Robertis, Riccardo Barbi, Emilio Salvia, Roberto Girelli, Roberto Paiella, Salvatore Gasparini, Camilla Cardobi, Nicolò Bassi, Claudio Percutaneous ablation of pancreatic cancer |
title | Percutaneous ablation of pancreatic cancer |
title_full | Percutaneous ablation of pancreatic cancer |
title_fullStr | Percutaneous ablation of pancreatic cancer |
title_full_unstemmed | Percutaneous ablation of pancreatic cancer |
title_short | Percutaneous ablation of pancreatic cancer |
title_sort | percutaneous ablation of pancreatic cancer |
topic | Editorial |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5124972/ https://www.ncbi.nlm.nih.gov/pubmed/27956791 http://dx.doi.org/10.3748/wjg.v22.i44.9661 |
work_keys_str_mv | AT donofriomirko percutaneousablationofpancreaticcancer AT ciaravinovalentina percutaneousablationofpancreaticcancer AT derobertisriccardo percutaneousablationofpancreaticcancer AT barbiemilio percutaneousablationofpancreaticcancer AT salviaroberto percutaneousablationofpancreaticcancer AT girelliroberto percutaneousablationofpancreaticcancer AT paiellasalvatore percutaneousablationofpancreaticcancer AT gasparinicamilla percutaneousablationofpancreaticcancer AT cardobinicolo percutaneousablationofpancreaticcancer AT bassiclaudio percutaneousablationofpancreaticcancer |